Literature DB >> 26408987

Administration of Lactobacillus helveticus NS8 improves behavioral, cognitive, and biochemical aberrations caused by chronic restraint stress.

S Liang1, T Wang2, X Hu2, J Luo3, W Li1, X Wu1, Y Duan2, F Jin2.   

Abstract

Increasing numbers of studies have suggested that the gut microbiota is involved in the pathophysiology of stress-related disorders. Chronic stress can cause behavioral, cognitive, biochemical, and gut microbiota aberrations. Gut bacteria can communicate with the host through the microbiota-gut-brain axis (which mainly includes the immune, neuroendocrine, and neural pathways) to influence brain and behavior. It is hypothesized that administration of probiotics can improve chronic-stress-induced depression. In order to examine this hypothesis, the chronic restraint stress depression model was established in this study. Adult specific pathogen free (SPF) Sprague-Dawley rats were subjected to 21 days of restraint stress followed by behavioral testing (including the sucrose preference test (SPT), elevated-plus maze test, open-field test (OFT), object recognition test (ORT), and object placement test (OPT)) and biochemical analysis. Supplemental Lactobacillus helveticus NS8 was provided every day during stress until the end of experiment, and selective serotonin reuptake inhibitor (SSRI) citalopram (CIT) served as a positive control. Results showed that L. helveticus NS8 improved chronic restraint stress-induced behavioral (anxiety and depression) and cognitive dysfunction, showing an effect similar to and better than that of CIT. L. helveticus NS8 also resulted in lower plasma corticosterone (CORT) and adrenocorticotropic hormone (ACTH) levels, higher plasma interleukin-10 (IL-10) levels, restored hippocampal serotonin (5-HT) and norepinephrine (NE) levels, and more hippocampal brain-derived neurotrophic factor (BDNF) mRNA expression than in chronic stress rats. Taken together, these results indicate an anti-depressant effect of L. helveticus NS8 in rats subjected to chronic restraint stress depression and that this effect could be due to the microbiota-gut-brain axis. They also suggest the therapeutic potential of L. helveticus NS8 in stress-related and possibly other kinds of depression.
Copyright © 2015 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BDNF; Lactobacillus helveticus; chronic restraint stress; depression; microbiota–gut–brain axis; serotonin

Mesh:

Substances:

Year:  2015        PMID: 26408987     DOI: 10.1016/j.neuroscience.2015.09.033

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  164 in total

Review 1.  The Microbiota, Immunoregulation, and Mental Health: Implications for Public Health.

Authors:  Christopher A Lowry; David G Smith; Philip H Siebler; Dominic Schmidt; Christopher E Stamper; James E Hassell; Paula S Yamashita; James H Fox; Stefan O Reber; Lisa A Brenner; Andrew J Hoisington; Teodor T Postolache; Kerry A Kinney; Dante Marciani; Mark Hernandez; Sian M J Hemmings; Stefanie Malan-Muller; Kenneth P Wright; Rob Knight; Charles L Raison; Graham A W Rook
Journal:  Curr Environ Health Rep       Date:  2016-09

2.  Differences in gut microbiota composition of laying hen lines divergently selected on feather pecking.

Authors:  Jerine A J van der Eijk; Hugo de Vries; Joergen B Kjaer; Marc Naguib; Bas Kemp; Hauke Smidt; T Bas Rodenburg; Aart Lammers
Journal:  Poult Sci       Date:  2019-12-01       Impact factor: 3.352

3.  Immunization with Mycobacterium vaccae induces an anti-inflammatory milieu in the CNS: Attenuation of stress-induced microglial priming, alarmins and anxiety-like behavior.

Authors:  Matthew G Frank; Laura K Fonken; Samuel D Dolzani; Jessica L Annis; Philip H Siebler; Dominic Schmidt; Linda R Watkins; Steven F Maier; Christopher A Lowry
Journal:  Brain Behav Immun       Date:  2018-05-26       Impact factor: 7.217

Review 4.  Cross-species examination of single- and multi-strain probiotic treatment effects on neuropsychiatric outcomes.

Authors:  Jamie M Joseph; Catrin Law
Journal:  Neurosci Biobehav Rev       Date:  2018-11-22       Impact factor: 8.989

Review 5.  Is Gut Dysbiosis an Epicenter of Parkinson's Disease?

Authors:  Charul Rajput; Alika Sarkar; Nidhi Sachan; Neeraj Rawat; Mahendra Pratap Singh
Journal:  Neurochem Res       Date:  2021-01-05       Impact factor: 3.996

Review 6.  What goes around comes around: novel pharmacological targets in the gut-brain axis.

Authors:  Camila González-Arancibia; Jorge Escobar-Luna; Camila Barrera-Bugueño; Camilo Díaz-Zepeda; María P González-Toro; Loreto Olavarría-Ramírez; Francesca Zanelli-Massai; Martin Gotteland; Javier A Bravo; Marcela Julio-Pieper
Journal:  Therap Adv Gastroenterol       Date:  2016-02-17       Impact factor: 4.409

7.  Stress and the Microbiota-Gut-Brain Axis: An Evolving Concept in Psychiatry.

Authors:  John F Cryan
Journal:  Can J Psychiatry       Date:  2016-02-23       Impact factor: 4.356

8.  Advances in understanding and treating mental illness: proceedings of the 40th Canadian College of Neuropsychopharmacology Annual Meeting Symposia.

Authors:  Catherine P Normandeau; Darya Naumova; Shawna Lee Thompson; Mohammad Ebrahimzadeh; Yu Qing Liu; Lauren Reynolds; Hong-Yan Ren; Emily R Hawken; Éric C Dumont
Journal:  J Psychiatry Neurosci       Date:  2017-09       Impact factor: 6.186

9.  Pharmacological restoration of gut barrier function in stressed neonates partially reverses long-term alterations associated with maternal separation.

Authors:  Marion Rincel; Maïwenn Olier; Amandine Minni; Camille Monchaux de Oliveira; Yann Matime; Eric Gaultier; Isabelle Grit; Jean-Christophe Helbling; Anna Maria Costa; Amandine Lépinay; Marie-Pierre Moisan; Sophie Layé; Laurent Ferrier; Patricia Parnet; Vassilia Theodorou; Muriel Darnaudéry
Journal:  Psychopharmacology (Berl)       Date:  2019-05-23       Impact factor: 4.530

10.  Methamphetamine exposure and its cessation alter gut microbiota and induce depressive-like behavioral effects on rats.

Authors:  Shadab Forouzan; Kristi L Hoffman; Therese A Kosten
Journal:  Psychopharmacology (Berl)       Date:  2020-10-23       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.